Preview

Научно-практическая ревматология

Расширенный поиск

Боль и воспаление. Часть 2. Анальгетический потенциал противовоспалительных препаратов

https://doi.org/10.14412/1995-4484-2017-58-67

Полный текст:

Аннотация

Воспалительная реакция и развитие боли – взаимозависимые процессы. Воспаление, сопровождающееся гиперпродукцией провоспалительных цитокинов и медиаторов, не только вызывает боль, но и является основной причиной ее хронизации. Поэтому главным направлением анальгетической терапии следует считать использование противовоспалительных препаратов. Во второй части обзора обсуждается анальгетический потенциал различных фармакологических групп, обладающих противовоспалительным действием, – нестероидных противовоспалительных препаратов, глюкокортикоидов, генно- инженерных биологических препаратов, метотрексата, медленно действующих противовоспалительных средств («хондропротекторов»), а также ряда перспективных и экспериментальных средств, таких как ингибиторы фактора роста нервов. Приводятся данные основных клинических исследований, в которых оценивалось обезболивающее действие этих препаратов при различных заболеваниях и патологических состояниях.

Об авторах

А. Е. Каратеев
ФГБНУ «Научно- исследовательский институт ревматологии им. В.А. Насоновой»
Россия

зав. лабораторией гастроэнтерологических проблем при ревматических заболеваниях ФГБНУ НИИР им. В.А. Насоновой, канд. мед. наук

115522 Москва, Каширское шоссе, 34А



Д. Е. Каратеев
ФГБНУ «Научно- исследовательский институт ревматологии им. В.А. Насоновой»
Россия

врио директора ФГБНУ НИИР им. В.А. Насоновой, докт. мед. наук

115522 Москва, Каширское шоссе, 34А



О. С. Давыдов
Научно-практический психоневрологический центр им. З.П. Соловьева Департамента здравоохранения г. Москвы
Россия

ведущий научный сотрудник Научно-практического психоневрологического центра им. З.П. Соловьева Департамента здравоохранения г. Москвы, канд. мед. наук

115419 Москва, ул. Донская, 43



Список литературы

1. Насонов ЕЛ. Противовоспалительная терапия ревматических болезней. Москва: М- СИТИ; 1996. 345 с. [Nasonov EL. Protivovospalitel’naya terapiya revmaticheskikh boleznei [Antiinflammatory therapy of rheumatic diseases]. Moscow: M-SITI; 1996. 345 p.].

2. Rainsford K. Anti-inflammatory drugs in the 21st century. Subcell Biochem. 2007;42:3-27. doi: 10.1007/1-4020-5688-5_1

3. Clauw DJ. Diagnosing and treating chronic musculoskeletal pain based on the underlying mechanism(s). Best Pract Res Clin Rheumatol. 2015 Feb;29(1):6-19. doi: 10.1016/j.berh.2015.04.024. Epub 2015 May 23.

4. Ennis ZN, Dideriksen D, Vaegter HB, et al. Acetaminophen for chronic pain: A systematic review on efficacy. Basic Clin Pharmacol Toxicol. 2016 Mar;118(3):184-9. doi: 10.1111/bcpt.12527. Epub 2015 Dec 28.

5. Botting R, Ayoub SS. COX-3 and the mechanism of action of paracetamol/acetaminophen. Prostaglandins Leukot Essent Fatty Acids. 2005 Feb;72(2):85-7. doi: 10.1016/j.plefa.2004.10.005

6. Graham GG, Davies MJ, Day RO, et al. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology. 2013 Jun;21(3):201-32. doi: 10.1007/s10787-013-0172-x. Epub 2013 May 30.

7. Machado G, Maher C, Ferreira P, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ. 2015 Mar 31;350:h1225. doi: 10.1136/bmj.h1225

8. Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti- inflammatory drugs. J Pain Res. 2015 Feb 20;8:105-18. doi: 10.2147/JPR.S75160. eCollection 2015.

9. Каратеев АЕ, Насонов ЕЛ, Яхно НН и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;9(1):4-23 [Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of nonsteroidal anti- inflammatory drugs (NSAIDs) in clinical practice». Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(1):4-23 (In Russ.)]. doi: 10.14412/1996-7012-2015-1-4-23

10. McCormack PL. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs. 2011 Dec 24;71(18):2457-89. doi: 10.2165/11208240-000000000-00000

11. Collantes E, Curtis S, Lee K, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Fam Pract. 2002;3:10. doi: 10.1186/1471-2296-3-10

12. Tarp S, Bartels EM, Bliddal H, et al. Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum. 2012 Nov;64(11):3511-21. doi: 10.1002/art.34644

13. Kroon FP, van der Burg LR, Ramiro S, et al. Non-steroidal antiinflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev. 2015 Jul 17;(7):CD010952. doi: 10.1002/14651858.CD010952.pub2

14. Benhamou M, Gossec L, Dougados M. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein. Rheumatology (Oxford). 2010 Mar;49(3):536-41. doi: 10.1093/rheumatology/kep393. Epub 2009 Dec 22.

15. Van Durme CM, Wechalekar MD, Buchbinder R, et al. Nonsteroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev. 2014 Sep 16;(9):CD010120. doi: 10.1002/14651858.CD010120.pub2

16. Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008 May 31;371(9627):1854-60. doi: 10.1016/S0140

17. Zweers M, de Boer T, van Roon J, et al. Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis. Arthritis Res Ther. 2011;13(5):239. doi: 10.1186/ar3437

18. Mehta V, Johnston A, Cheung R, et al. Intravenous parecoxib rapidly leads to COX-2 inhibitory concentration of valdecoxib in the central nervous system. Clin Pharmacol Ther. 2008 Mar;83(3):430-5. doi: 10.1038/sj.clpt.6100304. Epub 2007 Aug 8.

19. Nemeth CL, Glasper ER, Harrell CS, et al. Meloxicam blocks neuroinflammation, but not depressive-like behaviors, in HIV-1 transgenic female rats. PLoS One. 2014 Oct 1;9(10):e108399. doi: 10.1371/journal.pone.0108399. eCollection 2014.

20. Redondo-Castro E, Navarro X. Chronic ibuprofen administration reduces neuropathic pain but does not exert neuroprotection after spinal cord injury in adult rats. Exp Neurol. 2014 Feb;252:95-103. doi: 10.1016/j.expneurol.2013.11.008. Epub 2013 Nov 15.

21. Eisenach JC, Curry R, Rauck R, et al. Role of spinal cyclooxygenase in human postoperative and chronic pain. Anesthesiology. 2010 May;112(5):1225-33. doi: 10.1097/ALN.0b013e3181d94dc0

22. Goldstein JL, Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf. 2015 Jan 22;7:31-41. doi: 10.2147/DHPS.S71976. eCollection 2015.

23. Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821-47. doi: 10.18433/J3VW2F

24. Van der Goes MC, Jacobs JW, Bijlsma JW. The value of glucocorticoid co-therapy in different rheumatic diseases – positive and adverse effects. Arthritis Res Ther. 2014 Nov 13;16 Suppl 2:S2. doi: 10.1186/ar4686

25. Насонов ЕЛ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место глюкокортикоидов. Научно-практическая ревматология. 2015;53(3):238- 50 [Nasonov EL. New guidelines for the management of rheumatoid arthritis (EULAR, 2013): The place of glucocorticoids. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(3):238-50 (In Russ.)]. doi: 10.14412/1995-4484-2015-238-250

26. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011 Mar 15;335(1):2-13. doi: 10.1016/j.mce.2010.04.005. Epub 2010 Apr 14.

27. Gotzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev. 2004;(3):CD000189.

28. Friedman BW, Esses D, Solorzano C, et al. A randomized placebo-controlled trial of single-dose IM corticosteroid for radicular low back pain. Spine (Phila Pa 1976). 2008 Aug 15;33(18):E624-9. doi: 10.1097/BRS.0b013e3181822711

29. Abou-Raya A, Abou-Raya S, Khadrawi T, Helmii M. Effect of low-dose oral prednisolone on symptoms and systemic inflammation in older adults with moderate to severe knee osteoarthritis: a randomized placebo-controlled trial. J Rheumatol. 2014 Jan;41(1):53-9. doi: 10.3899/jrheum.130199. Epub 2013 Dec 1.

30. Hameed F, Ihm J. Injectable medications for osteoarthritis. PM R. 2012;4(5 Suppl):75-81. doi: 10.1016/j.pmrj.2012.02.010

31. Habib G, Saliba W, Nashashibi M. Local effects of intra-articular corticosteroids. Clin Rheumatol. 2010;29(4):347-56. doi: 10.1007/s10067-009-1357-y

32. Coombes BK, Bisset L, Vicenzino B. Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. Lancet. 2010 Nov 20;376(9754):1751-67. doi: 10.1016/S0140- 6736(10)61160-9. Epub 2010 Oct 21.

33. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3):363-88. doi: 10.1016/j.joca.2014.01.003. Epub 2014 Jan 24.

34. Насонов ЕЛ, редактор. Ревматология: Клинические рекомендации. 2-е изд. Москва: ГЭОТАР-Медиа; 2010 [Nasonov EL, editor. Revmatologiya: Klinicheskie rekomendatsii [Rheumatology: Clinical Guidelines]. 2nd ed. Moscow: GEOTARMedia; 2010].

35. Bjordal J, Klovning A, Ljunggren A, Slordal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials. Eur J Pain. 2007 Feb;11(2):125-38. doi: 10.1016/j.ejpain.2006.02.013.Epub 2006 May 8.

36. McCabe PS, Maricar N, Parkes MJ, et al. The efficacy of intraarticular steroids in hip osteoarthritis: A systematic review. Osteoarthritis Cartilage. 2016 Apr 30. pii: S1063- 4584(16)30056-5. doi: 10.1016/j.joca.2016.04.018. [Epub ahead of print].

37. Jü ni P, Hari R, Rutjes AW, et al. Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database Syst Rev. 2015 Oct 22;10:CD005328. doi: 10.1002/14651858.CD005328.pub3

38. Farooq M, Devitt A. Perceived efficacy and risks of infection following intra-articular injections: a survey of orthopaedic surgeons. Ir J Med Sci. 2005;174(1):26-32. doi: 10.1007/BF03168515

39. Charalambous C, Tryfonidis M, Sadiq S, et al. Septic arthritis following intraarticular glucocorticoid injection of the knee – a survey of current practice regarding antiseptic technique used during intra-articular glucocorticoid injection of the knee. Clin Rheumatol. 2003;22:386-90. doi: 10.1007/s10067-003-0757-7

40. Younes M, Neffati F, Touzi M, et al. Systemic effects of epidural and intra-articular glucocorticoid injections in diabetic and nondiabetic patients. Joint Bone Spine. 2007 Oct;74(5):472-6. doi: 10.1016/j.jbspin.2006.10.009. Epub 2007 Jul 6.

41. Moon HJ, Choi KH, Lee SI, et al. Changes in blood glucose and cortisol levels after epidural or shoulder intraarticular glucocorticoid injections in diabetic or nondiabetic patients. Am J Phys Med Rehabil. 2014 May;93(5):372-8. doi: 10.1097/PHM.0000000000000001

42. Chou R, Hashimoto R, Friedly J, et al. Pain management injection therapies for low back pain [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Mar. AHRQ Technology Assessments.

43. Pinto RZ, Maher CG, Ferreira ML, et al. Epidural corticosteroid injections in the management of sciatica: a systematic review and meta-analysis. Ann Intern Med. 2012 Dec 18;157(12):865-77. doi: 10.7326/0003-4819-157-12-201212180-00564

44. Staal JB, de Bie RA, de Vet HC, et al. Injection therapy for subacute and chronic low back pain: an updated Cochrane review. Spine (Phila Pa 1976). 2009 Jan 1;34(1):49-59. doi: 10.1097/BRS.0b013e3181909558

45. Ter Meulena B, Weinsteina H, Ostelob R, Koehlerd P. The epidural treatment of sciatica: its origin and evolution. Eur Neurol. 2016;75:58-64. doi: 10.1159/000443729

46. Pountos I, Panteli M, Walters G, et al. Safety of epidural corticosteroid injections. Drugs R D. 2016 Mar;16(1):19-34. doi: 10.1007/s40268-015-0119-3

47. Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно-практическая ревматология. 2014;52(1):8-26 [Nasonov EL, Karateev DE, Chichasova NV. New recommendations for the management of rheumatoid arthritis (EULAR, 2013): The role of methotrexate. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(1):8-26 (In Russ.)]. doi: 10.14412/1995- 4484-2014-8-26

48. Насонов ЕЛ. Метотрексат при ревматоидном артрите – 2015: новые факты и идеи. Научно-практическая ревматология. 2015;53(4):421-33 [Nasonov EL. Methotrexate in rheumatoid arthritis – 2015: New facts and ideas. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(4):421-33 (In Russ.)]. doi: 10.14412/1995-4484- 2015-421-433

49. Inoue K, Yuasa H. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. Drug Metab Pharmacokinet. 2014;29(1):12-9. doi: 10.2133/dmpk.DMPK-13-RV-119. Epub 2013 Nov 26.

50. Lopez-Olivo MA, Siddhanamatha HR, Shea B, et al. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2014 Jun 10;(6):CD000957. doi: 10.1002/14651858.CD000957.pub2

51. Li D, Yang Z, Kang P, Xie X. Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: A systematic review and meta-analysis. Semin Arthritis Rheum. 2016 Jun;45(6):656-62. doi: 10.1016/j.semarthrit.2015.11.004. Epub 2015 Dec 1.

52. Kalunian KC. Current advances in therapies for osteoarthritis. Curr Opin Rheumatol. 2016 May;28(3):246-50. doi: 10.1097/BOR.0000000000000273

53. Wenham C, Grainger AJ, Hensor EM, et al. Methotrexate for pain relief in knee osteoarthritis: an open-label study. Rheumatology (Oxford). 2013 May;52(5):888-92. doi: 10.1093/rheumatology/kes386. Epub 2013 Jan 7.

54. Kingsbury SR, Tharmanathan P, Arden NK, et al. Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase III trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial. Trials. 2015 Mar 4;16:77. doi: 10.1186/s13063-015-0602-8

55. Насонов ЕЛ. Прогресс ревматологии в начале XXI века. Современная ревматология. 2014;8(3):4-8 [Nasonov EL. Progress in rheumatology in the early 21st century. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2014;8(3):4-8 (In Russ.)]. doi: 10.14412/1996-7012-2014-3-4-8

56. Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. 549 с. [Nasonov EL, editor. Gennoinzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological agents in the treatment of rheumatoid arthritis]. Moscow: IMA- PRESS; 2013. 549 p.].

57. Jansen JP, Buckley F, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysis. Health Qual Life Outcomes. 2014 Jul 3;12:102. doi: 10.1186/1477-7525-12-102

58. Chevalier X, Goupille P, Beaulieu AD, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2009 Mar 15;61(3):344-52. doi: 10.1002/art.24096

59. Pimentel D, El Abd O, Benyamin R, et al. Anti-tumor necrosis factor antagonists in the treatment of low back pain and radiculopathy: a systematic review and meta-analysis. Pain Physician. 2014 Jan-Feb;17(1):E27-44.

60. Miller CG, Guermazi A, Roemer F. The current status of imaging in anti-NGF clinical trials. Osteoarthritis Cartilage. 2015 Jan;23 Suppl 1:S3-7. doi: 10.1016/j.joca.2014.09.002

61. Ekman EF, Gimbel JS, Bello AE, et al. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen. J Rheumatol. 2014 Nov;41(11):2249-59. doi: 10.3899/jrheum.131294. Epub 2014 Oct 1.

62. Spierings EL, Fidelholtz J, Wolfram G, et al. A phase III placeboand oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain. 2013 Sep;154(9):1603- 12. doi: 10.1016/j.pain.2013.04.035. Epub 2013 Apr 22.

63. Kan SL, Li Y, Ning GZ, et al. Tanezumab for patients with osteoarthritis of the knee: A meta-analysis. PLoS One. 2016 Jun 13;11(6):e0157105. doi: 10.1371/journal.pone.0157105. eCollection 2016.

64. Leite VF, Buehler AM, El Abd O, et al. Anti-nerve growth factor in the treatment of low back pain and radiculopathy: A systematic review and a meta-analysis. Pain Physician. 2014;17:45-60.

65. Алексеева ЛИ. Препараты замедленного действия в лечении остеоартроза. Русский медицинский журнал. 2012;(7):389-94 [Alekseeva LI. Slow-acting drugs in the treatment of osteoarthritis. Russkii Meditsinskii Zhurnal. 2012;(7):389-94 (In Russ.)].

66. Au R, Au A, Rashmir-Raven A, Frondoza C. Inhibition proinflammatory gene expression in chondrocytes, monocytes, and fibroblasts by combination of avocado soybean unsaponiables, glucosamine and chondroitin sulfate. FASEB. 2007;21(6):702-7.

67. Towheed T, Maxwell L, Anastassiades T, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002946. doi: 10.1002/14651858.cd002946.pub2

68. Reichenbach S, Sterchi R, Scherer M, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med. 2007;146(8):580-90. doi: 10.7326/0003-4819-146-8- 200704170-00009

69. Fidelix T, Soares B, Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005117. doi: 10.1002/14651858.cd005117.pub2

70. Christensen R, Bartels E, Astrup A, Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2008;16(4):399-408. doi: 10.1016/j.joca.2007.10.003

71. Singh G, Alekseeva L, Alexeev V, Triadafilopoulos G. Glucosamin-chondroitin sulfate reduces pain, disability and NSAID consumption in patients with chronic low back pain: a large, community-based, pilot, open prospective observational study. EULAR; 2013, SAT0419.

72. Каратеев АЕ, Алексеева ЛИ. Оценка переносимости диацереина в реальной клинической практике. Результаты исследования РОКАДА (Ретроспективная Оценка Клинических Аспектов применения Диафлекса при остеоАртрозе). Научно- практическая ревматология. 2015;53(2):169-74 [Karateev AE, Alekseeva LI. Estimation of diacerein tolerability in real clinical practice: Results of the RACADA (Retrospective Assessment of Clinical Aspects of using Diaflex in osteoArthritis). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(2):169-74 (In Russ.)]. doi: 10.14412/1995-4484-2015-169-174

73. Kulkarni SK, Singh VP. Licofelone: the answer to unmet needs in osteoarthritis therapy? Curr Rheumatol Rep. 2008 Jan;10(1):43-8. doi: 10.1007/s11926-008-0008-7

74. Bertolini A, Ottani A, Sandrini M. Dual acting anti-inflammatory drugs: a reappraisal. Pharmacol Res. 2001 Dec;44(6):437-50. doi: 10.1006/phrs.2001.0872

75. Raynauld JP, Martel-Pelletier J, Bias P, et al. Protective effects of licofelone, a 5- lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis. 2009 Jun;68(6):938-47. doi: 10.1136/ard.2008.088732. Epub 2008 Jul 23.

76. Kawaguchi A, Sugimoto K, Fujimura A. Preventive effect of platelet-activating factor antagonist, Y-24180, against cyclosporine-induced acute nephrotoxicity. Life Sci. 2001 Jan 26;68(10):1181-90. doi: 10.1016/S0024-3205(00)01028-6

77. Thurmond RL, Desai PJ, Dunford PJ, et al. A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther. 2004 Apr;309(1):404-13. doi: 10.1124/jpet.103.061754. Epub 2004 Jan 13.

78. Cowden JM, Yu F, Banie H, et al. The histamine H4 receptor mediates inflammation and Th17 responses in preclinical models of arthritis. Ann Rheum Dis. 2014;73(3):600-8. doi: 10.1136/annrheumdis-2013-203832

79. Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015;55:533-52. doi: 10.1146/annurev-pharmtox-010814-124701. Epub 2014 Oct 8.

80. Gang Yao, Tingmin Yu, Ximei Han, et al. Therapeutic effects and safety of olcegepant and telcagepant for migraine: A meta-analysis. Neural Regen Res. 2013 April 5;8(10):938-47. doi: 10.3969/j.issn.1673-5374.2013.10.009

81. Bigal ME, Walter S, Rapoport AM Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015 Jun;79(6):886-95. doi: 10.1111/bcp.12591

82. O'Byrne PM. Asthma treatment: antileukotriene drugs. Can Respir J. 1998 Jul-Aug;5 Suppl A:64A-70A.

83. Cingi C, Muluk N, Ipci K, Sahin E. Antileukotrienes in upper airway inflammatory diseases. Curr Allergy Asthma Rep. 2015 Nov;15(11):64. doi: 10.1007/s11882-015-0564-7

84. Deeks ED. Icatibant. Drugs. 2010;70(1):73-81. doi: 10.2165/11204500-000000000-00000

85. Tricco AC, Soobiah C, Blondal E, et al. Comparative safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis. BMC Med. 2015 Jun 18;13:142. doi: 10.1186/s12916-015-0379-3

86. Liu M, Zhang H, Du BX, et al. Neurokinin-1 receptor antagonists in preventing postoperative nausea and vomiting: a systematic review and meta-analysis. Medicine (Baltimore). 2015 May;94(19):e762. doi: 10.1097/MD.0000000000000762

87. Ogawa S, Awaga Y, Takashima M, et al. Knee osteoarthritis pain following medial meniscectomy in the nonhuman primate. Osteoarthritis Cartilage. 2016 Jul;24(7):1190-9. doi: 10.1016/j.joca.2016.02.006. Epub 2016 Mar 2.

88. Iyer JP, Srivastava PK, Dev R, et al. Prostaglandin E(2) synthase inhibition as a therapeutic target. Expert Opin Ther Targets. 2009 Jul;13(7):849-65. doi: 10.1517/14728220903018932

89. Mbalaviele G, Pauley AM, Shaffer AF, et al. Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor. Biochem Pharmacol. 2010 May 15;79(10):1445-54. doi: 10.1016/j.bcp.2010.01.003. Epub 2010 Jan 11.

90. Ganesh T. Prostanoid receptor EP2 as a therapeutic target. J Med Chem. 2014 Jun 12;57(11):4454-65. doi: 10.1021/jm401431x. Epub 2013 Dec 4.

91. Sugita R, Kuwabara H, Kubota K, et al. Simultaneous inhibition of PGE2 and PGI2 signals is necessary to suppress hyperalgesia in rat inflammatory pain models. Mediators Inflamm. 2016;2016:9847840. doi: 10.1155/2016/9847840. Epub 2016 Jul 13.

92. Headland SE, Norling LV. The resolution of inflammation: Principles and challenges. Semin Immunol. 2015 May;27(3):149-60. doi: 10.1016/j.smim.2015.03.014. Epub 2015 Apr 22.

93. Serhan CN, Dalli J, Colas RA, et al. Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. Biochim Biophys Acta. 2015 Apr;1851(4):397-413. doi: 10.1016/j.bbalip.2014.08.006. Epub 2014 Aug 17.

94. Cholkar K, Gilger BC, Mitra AK. Topical delivery of aqueous micellar resolvin E1 analog (RX-10045). Int J Pharm. 2016 Feb 10;498(1-2):326-34. doi: 10.1016/j.ijpharm.2015.12.037. Epub 2015 Dec 17.


Для цитирования:


Каратеев А.Е., Каратеев Д.Е., Давыдов О.С. Боль и воспаление. Часть 2. Анальгетический потенциал противовоспалительных препаратов. Научно-практическая ревматология. 2017;55(1):58-67. https://doi.org/10.14412/1995-4484-2017-58-67

For citation:


Karateev A.E., Karateev D.E., Davydov O.S. PAIN AND INFLAMMATION. PART 2. THE ANALGESIC POTENTIAL OF ANTI-INFLAMMATORY DRUGS. Rheumatology Science and Practice. 2017;55(1):58-67. https://doi.org/10.14412/1995-4484-2017-58-67

Просмотров: 703


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)